Q-omics provides the consensus-scored RRP7A profile across patient tissues and cancer cell-line models. RRP7A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RRP7A is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, RRP7A protein abundance shows 22,316 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, and LSCC as cancer lineages where RRP7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRP7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRP7A survival associations across molecular data types. RRP7A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRP7A RNA expression–survival associations across cancer types. High RRP7A expression shows unfavorable associations in LIHC, ACC, UVM and MESO, but favorable associations in SCLC and UCEC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RRP7A RNA expression.
This table summarizes RRP7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RRP7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRP7A shows higher tumor expression in LIHC, STAD, HNSC, COAD, BLCA and LUSC. The LIHC box plot shows higher RRP7A RNA expression in tumor versus normal tissue (log2 FC = +1.336, t-test p < 0.001).
This table shows molecular features associated with RRP7A in patient tissues and cancer cell lines. In patient samples, RRP7A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RRP7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
